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Advances in supportive care have led to significant
improvements in hematopoietic cell transplant (HCT)
outcomes over the last decade. Although children
with acute leukemia previously had rates of 1-year
transplant-related mortality (TRM) following unre-
lated donor HCT approaching 40%, in a more recent
era, these rates have fallen bymore than half to approx-
imately 15% [1]. This has led to significantly more
alternative donor HCTs being performed for a wide
variety of nonmalignant diseases, including primary
immunodeficiencies (of T cells and/or phagocytes),
hemoglobinopathies, bone marrow failure syndromes,
and metabolic syndromes. Unlike a typical patient
with leukemia, who enters HCT having received
months of immunosuppressive chemotherapy, many
patients with a nonmalignant disorder will begin the
conditioning regimen with a fully intact immune sys-
tem. This places those patients at very high risk for
graft rejection, which forces transplant physicians to
employ preparative regimens that are highly immu-
noablative. Even patients who enter HCT with defec-
tive immune systems, such as those with severe aplastic
anemia or hemophagocytic lymphohistiocytosis, tend
to require significant immunoablation because of an
underlying disposition toward attacking bone marrow
elements such as transplanted hematopoietic stem
cells.
This increased pre-HCT immunoablation often
leads to delays in post-HCT immune reconstitution,
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6/j.bbmt.2011.10.024tions, including autoimmune cytopenias, opportunis-
tic infections, and Epstein-Barr virus (EBV)-related
posttransplant lymphoproliferative disease (PTLD).AUTOIMMUNE CYTOPENIAS FOLLOWING
HCT FOR NONMALIGNANT DISORDERS
Autoimmune cytopenias occurring before and af-
ter allogeneic HCT are common, whereas the litera-
ture on the topic is sparse. In part, this is because the
diagnosis is not always suspected (cytopenias are often
seen in the early posttransplant period and may be
multifactorial), and the diagnostic workup is not en-
tirely straightforward. In some circumstances, watch-
ful waiting with minimal intervention, even over
a period of months, is appropriate. In other cases, mul-
tiagent therapy is indicated, as with life-threatening
neutropenia or thrombocytopenia.
Pathophysiology
Bone marrow transplantation can both transmit
and eliminate autoimmune disease. Imbalance be-
tween autoreactive and autoregulatory lymphocytes
underlies the development and persistence of autoim-
mune cytopenias.
Pretransplant
Manypatientswithnonmalignantdisorders showev-
idence of autoimmune cytopenias pretransplant [2-6].
Perhaps the most challenging disorder in this regard is
ALPS (autoimmune lymphoproliferative syndrome).
ALPS, caused by defective lymphocyte homeostasis
because of mutations in multiple genes, but most
commonly fetal alcohol syndrome, is characterized by
nonmalignant lymphoproliferation (lymphadenopathy,
hepatosplenomegaly with or without hypersplenism),
autoimmune disease mostly directed toward blood
cells, and life-long increased risk of both Hodgkin and
non-Hodgkin lymphoma. Pretransplant, the patients
may require two or more immunosuppressive agents to
control autoimmunity. To date, HCT has been per-
formed only in the most severe and drug-resistant cases.
In the experience at Cincinnati Children’s, severeS101
S102 Biol Blood Marrow Transplant 18:S101-S110, 2012C. C. Dvorak et al.posttransplant immune cytopenias can persist for 2 years
ormore despite treatment withmultiple agents and plas-
mapheresis—but the patients finally recover and spleno-
megaly resolves.
Other immunodeficiency disorders associated with
a high incidence of pretransplant immune cytopenias
include Omenn syndrome (sometimes referred to as
‘‘leaky’’ severe combined immunodeficiency [SCID])
and Wiskott Aldrich syndrome (WAS). Omenn syn-
drome is most often caused by hypomorphicmutations
in recombinase genes RAG-1 and RAG-2, which im-
pair but do not eliminate recombination of variable,
diversity, and joining segments of TCR and Ig genes.
Many other SCID defects have also been associated
with immune cytopenias pretransplant. Omenn syn-
drome is no longer viewed as a specific form of
SCID but rather as an aberrant inflammatory condi-
tion that can significantly impair (but not abolish)
T cell development in the thymus. In this way, it
resembles some features of chronic graft-versus-host
disease (cGVHD) (information to follow).
Immune cytopenias have been documented in high
proportions of untransplanted patients withWAS, usu-
ally apparent before 5 years of age. Reported incidence
ranges between the reports from the Necker Hospital,
Paris: autoimmune hemolytic anemia (36%), autoim-
mune neutropenia (25%) [7], to 50% of patients
experiencing one or more autoimmune cytopenias
pretransplant in the current era (experience of the
Cincinnati Children’sHospitalMedical Center). Severe
thrombocytopenia in WAS may not only be because of
the intrinsic defect in platelet production but addition-
ally to the development of antiplatelet autoantibodies.
Severe thrombocytopenia recurring after splenectomy
is particularly ominous in regard to heightened risk of
life-threatening hemorrhage. The etiology of the high
risk of developing autoimmunity inWAS is not yet fully
understood butmay involve a combination of factors re-
sulting from the underlying gene defect including defec-
tive motility and polarization of a number of
hematologic cells, decreased number and function of
regulatoryT cells (Tregs), susceptibility to autoimmune
triggers such as cytomegalovirus (CMV) infection, and
a chronically inflamed milieu.
In addition to the disorders previously mentioned,
pretransplant autoimmune cytopenias can be seen in
IPEX syndrome (failure to generate Tregs) and a vari-
ety of marrow failure syndromes some of which
demonstrate significant deficiencies in B and natural
killer (NK) cells.
Posttransplant
Causes of posttransplant immune cytopenias are
multiple. In a minority of cases, transfer of ‘‘patho-
logic’’ lymphocytes from an autoimmune-prone donor
can occur. More commonly, host plasma cells persist
and continue to manufacture autoantibodies formany months in the bone marrow and lymphoid tis-
sues despite myeloablative conditioning therapy. Reg-
ulatory control of existing or emerging autoimmune
lymphocytes is also not established until the latter
part of the first posttransplant year, or later, specifically
the emergence of significant numbers of natural Tregs.
Many of the immunosuppressive agents frequently
used to prevent acute GVHD such as steroids and cal-
cineurin inhibitors are not fully effective in controlling
the autoimmunity.
Acute GVHD and cGVHD contribute to the de-
velopment of an autoimmune-prone milieu [8].
GVHD-attributable autoimmunity is associated with
a paucity of CD41CD251Foxp31 regulatory T cells.
In animal models, this favors the expansion of donor-
derived CD41T cells of the Th1 and Th17 proinflam-
matory cytokine phenotypes. These T cells interact
with donor-derived antigen-presenting cells, favoring
and sustaining an immunologic environment that fa-
vors de novo development of autoantibodies to
donor-derived hematopoietic cells [9].
The incidence of posttransplant autoimmune
cytopenias has not been described for most nonmalig-
nant disorders. One exception is infants with SCID
undergoing nonmyeloablative HCT [10]. WAS is the
other exception. In a recent retrospective review of
194 patients transplanted for WAS from multiple
centers around the world between 1980 and 2009, ret-
rospective analysis of lineage-specific donor cell
engraftment showed that stable full-donor chimerism
was attained by 72.3% of the patients who survived
for at least 1 year after HCT. Mixed chimerism was
associated with an increased risk of incomplete recon-
stitution of lymphocyte count and post-HCT autoim-
munity [11]. This is in accordance with an earlier
report from the European Bone Marrow Transplant
Group reporting on 96 patients who underwent trans-
plantation between 1979 and 2001 who survived at
least 2 years [12]. Autoimmunity independent of
cGVHD was associated with persistent mixed chime-
rism (note: there is significant overlap of subjects be-
tween the two studies).
The incidence of post-HCT autoimmune cytope-
nias was recently analyzed in the series of patients with
WAS transplanted during 2001 to 2009 at Cincinnati
Children’s Hospital Medical Center when screening
for autoimmune cytopenias was routinely performed.
Seventeen of 31 patients (55%) had clinically evident
immune-mediated cytopenias documented by analysis
for relevant autoantibodies. Trilineage cytopenias
were detected in one of 31 patients (3%), dual cytope-
nias were detected in eight of 31(26%), and single cy-
topenias were detected in eight of 31 patients (26%).
The most common cytopenia detected was thrombo-
cytopenia in 13 of 31 (42%), followed by autoimmune
neutropenia in 11 of 31 (35%) patients, and autoim-
mune hemolytic anemia in three of 31 (10%). Time
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with amedian of 148 days (range, 33-467 days) but typ-
ically occurring within the first 6 months post-HCT.
Occurrence of autoimmune cytopenias did not corre-
late with the presence of acute GVHD (grades II-IV,
P 5 .71), cGVHD (P 5 .12) or with mixed chimerism
(P5 .50; all Fisher exact test). Fourteen of 17 patients
developed autoantibodies independent of cGVHD.
Autoimmune cytopenias resolved in the majority of
patients with complete resolution in 11/17 (65%)
patients at present and ongoing improvement in four
more recent patients. The median time to recovery
of normal blood counts in this group was 429 days
(range, 131-979 days) from the time of HCT, indicat-
ing that management of posttransplantation autoim-
mune complications need be prolonged in this
population but that resolution can be obtained in the
majority of patients.
Diagnosis
Immune cytopenias are suspected when levels of
hemoglobin, neutrophils, and/or platelets do not rise
as expected weeks or months after HCT, or, once
recovered or normalized, the levels begin to decline.
It is helpful to check the level of overall or
lineage-specific engraftment with some regularity, be-
cause many patients with nonmalignant disorders
receive reduced-intensity conditioning, and informa-
tion regarding the status of engraftment may influence
the intervention that is ultimately selected.
An elevated reticulocyte count is consistent with
AIHA. Bone marrow biopsies are often performed: if
there is robust cellularity—peripheral destruction is
highly likely. However, the finding of a hypoplastic
marrow does not preclude an autoimmune process.
Testing for antibodies against the patient’s neutrophil
and platelet-specific antigens largely confirms the
diagnosis. Such autoantibody testing is performed in
a few specialty laboratories in North America, and
may require a 2- to 3-week turnaround.
Therapy
Similar approaches are used and have similar
efficacy inboth thepre- andposttransplantation setting.
Conventional measures include corticosteroid dosing
to2mg/kg and infusionof highdosesof intravenous im-
munoglobulin to achieve a minimum sustained trough
level of around 2,000 intended to reduce rapid splenic
uptake of autoantibody-coated cells.
Rituximab, typically administered as four weekly
doses, is now commonly administered both pre- and
posttransplantation, especially in cases of primary im-
munodeficiencies [13,14]. In refractory cases,
rituximab has been combined with plasmapheresis with
anecdotal success in pediatric HCT. Sirolimus, shown
to be useful in ALPS, also appears to benefit some
cases of post-HCT immune cytopenias [15,16].The newest approach to be considered is bortezo-
mib, a proteasome inhibitor, combined with plasma-
pheresis, administered in repeated cycles. This is the
first effective treatment to block pathologic plasma
cells. It has shown promise in reversing allosensitiza-
tion in solid-organ transplantation [17]. Trials to con-
trol autoimmune cytopenias in the HCT setting are
just beginning.OPPORTUNISTIC INFECTIONS: TOWARD
RISK-ADAPTED PROPHYLAXIS STRATEGIES
Infections with opportunistic organisms are one of
the most common posttransplantation complications.
Multiple therapy-induced alterations of host defenses
contribute to this risk [18]. The three major contribu-
tors to the development of an opportunistic infection
(OI) are breakdown in natural barriers (such as
indwelling catheter and mucositis), defects in cell-
mediated immunity (lymphopenia from corticoste-
roids and other anti-T cell cytotoxic agents), and
deficient numbers of phagocytes (because of myeloa-
blative chemotherapy). Classically, three phases of
infections have been noted: (1) prior to engraftment
(mainly bacteremias, herpes simplex virus, candidemia,
and invasive aspergillosis [IA]); (2) the early posten-
graftment period until approximately day 1100
(mainly Gram-positive bacteremias, candidemia, and
CMV and other double-strand [ds] DNA viruses);
and (3) the late period following day 1100 (mainly
encapsulated bacteria, IA, Pneumocystis jiroveci, and
continuing problems with dsDNA viruses) [19].
In addition to causing significantmorbidity and pro-
longed hospitalizations, OIs cause 37% to 40%of TRM
following allogeneic HCT [20]. The first step toward
preventing OI in patients with nonmalignant disease
lies in defining risk groups. For example, one of the sim-
plest ways to segregate HCT recipients is by the donor
stem cell source (bone marrow versus peripheral blood
stemcell versus umbilical cord blood [UCB]).The recip-
ients of more mismatched allogeneic donors tend to be
much more immunosuppressed, initially in order to
overcome HLA barriers and to hopefully prevent the
developmentofGVHDand then later,whenundergoing
treatment forGVHD.This, in turn, leads tomoreOI, as
is seen inboth recipients ofUCB transplants (reviewed in
[21]), aswell as thoseundergoing ex vivoTcell depletion,
where a prospective trial found a significantly higher in-
cidence of severe CMV and IA compared with those re-
ceiving standard cyclosporine and methotrexate for
GVHD prophylaxis [22].
Current Prophylaxis Strategies: Medications
versus Cellular Therapy
Current strategies used for post-HCT prophylaxis
of OIs generally utilize antimicrobial medications,
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adoptive immunotherapy for potential future use as
OI prevention.
Antibacterial prophylaxis has been widely used in
adult patients undergoing HCT. A meta-analysis of
95 randomized trials showed that, in adults, antibacte-
rial prophylaxis significantly decreased the risk of all-
cause mortality [23], so that the combined HCT
guidelines state that prophylaxis with a fluoroquino-
lone should be strongly considered [19]. Because the
data in children are so limited, no recommendation
could be made. Therefore, in mid-2011, the Chil-
dren’s Oncology Group (COG) embarked upon a pro-
spective trial designed to definitively answer the
question of the utility of this strategy. Given the known
risk of neutropenia contributing to the development of
bacteremia, another approach would be to use prophy-
lactic granulocyte transfusions during the first several
weeks post-HCT. However, a meta-analysis of 10
older trials evaluating this approach in adults failed
to show improvement in mortality [24]; however,
given interval advances in supportive care, it is still
conceivable that a carefully designed trial with large
granulocyte doses could show a benefit.
Conversely, antifungal prophylaxis is widely used
in pediatric HCT recipients, despite the fact that there
are almost no data in children\12 years of age. Based
on two pivotal trials published over 15 years ago
[25,26], fluconazole is still the most common agent
of choice, even in higher-risk alternative donor
HCT, although more centers are now using
theoretically superior mold-active agents, despite
a paucity of data demonstrating actual superiority
(56% of centers use fluconazole, 28% use voricona-
zole, 11%use an echinocandin, and 5%use a liposomal
form of amphotericin B; C. Dvorak, unpublished data
from 2011 survey of COG HCT centers). Because of
the profound lack of pediatric-specific data, in late
2011, the COG plans to initiate a prospective trial of
caspofungin prophylaxis compared with fluconazole
or voriconazole in alternative donor HCT. Another
interesting approach lies in the creation of Aspergil-
lus-specific T cells, which in haploidentical HCT re-
cipients has been shown to improve resolution rates
of documented IA [27].
Other than the use of early acyclovir to prevent
HSV reactivation, medication-based prophylactic
strategies for viral infections post-HCT have been
limited by the toxicities of the available agents. As of
2005, only 15% of pediatric HCT centers used
ganciclovir in a prophylactic strategy against CMV,
with the majority using preemptive treatment guided
by highly sensitive polymerase chain reaction (PCR)
monitoring [28]. However, the advent of CMX-001,
a potentially less-toxic lipid formulation of cidofovir,
an agent with broad activity against dsDNA viruses,
has reopened the door regarding the utility of a pro-phylaxis strategy in high-risk patients. Adult studies
of this agent are underway, and a pediatric trial is being
planned. In addition, significant strides have been
made in the creation of donor T cell-specific dsDNA
viruses have shown an ability to prevent reactivation
of CMV [27] and EBV [29] following high-risk
HCT, and this approach could also be applied to
adenovirus [29].
The most significant problem with the creation of
infection-specific T cells is that a different T cell prod-
uct needs to be developed for each potential infection
that a patient may encounter, which can be time con-
suming and expensive. Thus, most trials of these cells
are currently being done in patients to treat an active
infection. Although certainly a ‘‘cocktail’’ containing
a mixture of several different virus-specific T cells
could be produced [30], others have evaluated the
possibility of utilized infusions of alloreactive-
depleted T cells [31].
Finally, although some of the newer antimicrobial
agents and the virus-specific T cells are quite exciting,
it is unlikely that any of these agents will prove to be
completely free of unintended side effects. Therefore,
the question must be asked: Should everyone receive
antimicrobial prophylaxis, or can we begin to deter-
mine who exactly are the highest-risk patients and
target our prophylaxis strategies upon them?Bacteremia: Gram-Negative Rods and Beyond
Bacteremia, most importantly from Gram-
negative rods, is commonly encountered during the
neutropenic period post-HCT, with incidences rang-
ing from as low as 21% for matched related donors
to as high as 76% for alternative donor recipients
and with an appreciable mortality rate of 11% to
18% [32,33]. As noted previously, efforts are
underway to determine if pediatric patients would
benefit from the administration of prophylactic
antibiotics post-HCT; however, any pharmaceutical
prophylaxis regimen will always carry a risk of induc-
ing the development of resistant organisms. Clearly,
the optimal strategy would be to identify which pa-
tients, are at highest risk and only utilize prophylaxis
in those individuals. However, besides neutropenia
and the presence of central venous catheters, there
are few accepted risk factors for the development of
bacteremia. One commonly held belief is that bacter-
emia is more common in those with impaired mucosal
integrity because of cytoreductive chemo- or radio-
therapy. However, other than the known risk of a-he-
molytic Streptococcal infections following cytarabine
therapy, individuals appear to have variable suscepti-
bilities to conditioning agents, and there is no easy
method for measuring mucosal damage outside of
the mouth, making broad associations of bacteremia
to specific agents difficult. Several studies have shown
Table 1. Genetic Risk Factors for the Development of Opportunistic Infection Following Allogeneic HCT
Type of Infection Gene Polymorphism
Source
of DNA
Number of
HCTs Studied Hypothetical mechanism Reference
Severe bacterial infection MPO Donor 107 Less production of MPO Rocha et al., 2002 [34]
Severe bacterial infection PTPN22 Donor 192 Unknown Azarian et al., 2008 [35]
Bacteremia P2X7 receptor Donor 145 Less production of IL-1 Lee et al., 2007 [36]
GN Bacteremia LBP Host 234 Less production of LBP Chien et al., 2008 [37]
GN Bacteremia TLR4 Donor 77 Blunted response to LPS Mensah et al., 2009 [38]
CN Staphylococcus NOD2 Host 85 Reduced defensin production Van der Velden et al., 2009 [39]
IA TLR1 and TLR6 Host 127 Decreased recognition by phagocytes Kesh et al., 2005 [46]
IA IL-10 promoter Host 105 Less production of IL-10 Seo et al., 2005 [47]
IA Plasminogen Host 236 Increased tissue damage and invasion Zass et al., 2008 [48]
IA TLR4 Donor 366 Decreased recognition by phagocytes Bochud et al., 2008 [49]
IA Chemokine ligand 10 Donor 139 Less response to IFN-g, so less TH1 cells Mezger et al., 2008 [50]
IA Dectin-1 Both 205 Less production of IFN-g and IL-10 Cunha et al., 2010 [51]
IFI MBL Donor 106 Decreased complement fixation Granell et al., 2006 [52]
IFI MASP2 Host 106 Decreased complement fixation Granell et al., 2006 [52]
CMV INF-g Host 92 Less production of IFN-g, so less TH1 cells Jaskula et al., 2009 [56]
EBV INF-g Host 83 Less production of IFN-g, so less TH1 cells Bogunia-Kubik et al., 2006 [57]
EBV CCR5 Host 92 Decreased infectivity of EBV? Bogunia-Kubik et al., 2007 [58]
GN indicates Gram negative; CN, coagulase negative; IA, invasive Aspergillosis; MPO, myeloperoxidase; IL, interleukin; LPS, binding protein; LPS, lipopoly-
saccharide (bacterial); IFN, interferon; TH1, T helper 1.
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sponsible for immunity contribute to the risk of bacte-
rial infections (Table 1) [34-39].
Invasive Fungal Infections: Candidemia and
Invasive Aspergillosis
Depending on donor source and prophylaxis regi-
men, invasive fungal infections (IFI) occur in 13% to
20% of pediatric HCT recipients by 1 year post-
HCT, with a 58% to 83% mortality rate [40-45].
Candida spp. are most commonly encountered during
the neutropenic period in the first several weeks
following HCT, while Aspergillus spp. have a bimodal
distribution, with a first peak at a median of 16 days
and the second at a median of 96 days postallogeneic
HCT [22]. Given the now-universal use of prophylaxis,
one surprising feature to note from theoriginal flucona-
zole studies is that, even in the placebo arm, .80% of
patients did not develop an IFI, although these studies
did include lower-risk autologous HCT recipients
[25,26]. Therefore, there must be other explanations
for the development of IFI post-HCT. As mentioned
previously, multiple gene polymorphisms appear to
play a significant role in IFI risk (Table 1) [46-52].
Part of the COG trial will be to validate in
a homogenously treated cohort these and other
polymorphisms that predispose to the development of
IFIs in immunocompromised hosts, so as to fully
define an individual patient’s genetic risk.
dsDNAViruses: CMV, EBV, and Adenovirus
In recipients of UCBTs, where OIs represent
.50% of TRM, two infections alone represented
.50% of OI-related deaths: adenovirus and CMV
[21]. Other than donor and recipient serostatus, the
major risk factor for the development of dsDNA viralinfections post-HCT is clearly the use of serotherapy
[53-55]. In addition, as with other infections, a few
polymorphisms have been shown to contribute to the
development of dsDNA viral infections following
HCT (Table 1) [56-58]. Other polymorphisms have
been implicated in the development of dsDNA viral
infections in solid- organ transplantation recipients
but remain to be evaluated in HCT patients.
Risk Stratification: Individualized Prophylaxis
Strategies?
There are several barriers to the immediate
implementation of genetic risk factors into a risk-
stratification system.Thefirst is thatmost of these poly-
morphisms have been identified in small (median
sample size 5 107 HCTs) single-center studies and
need to be confirmed in larger multicenter trials. Fur-
thermore, most of these tests remain research tools
and are not yet commercially available. However,
once these issues have been dealt with, we will then be
able to combine disease- and transplant-specific clinical
risk factors, with the genetic susceptibility of the host
anddonor in order to build risk-stratification groupings
forpatientsundergoingHCTfor treatmentof anonma-
lignant disorder. We can then begin to employ risk-
adapted therapies, where ‘‘low-risk’’ patients may
potentially receive no prophylaxis (and thusminimizing
the emergence of emergence of drug-resistant organ-
isms and medication side effects) but would undergo
careful monitoring (with optimized serum biomarkers)
and preemptive intervention only in the setting of rising
markers (analogous to preemptive therapy of CMV
based on quantitative PCR). ‘‘Standard-risk’’ patients
could potentially receive logistically simple drug-
based monotherapy, with the best agents identified in
the current pediatric-specific prospective trials, and
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future trials, such as combinations of anti-infective
pharmaceuticals with cellular therapies.DIAGNOSIS AND MANAGEMENTOF EBV
REACTIVATION OF PTLD
POSTTRANSPLANT
Viral Latency and EBV Lymphomas
EBV is a dsDNA virus and a member of the gam-
maherpes subfamily. It causes a variety of clinical pre-
sentations in the immune-competent host ranging
from a self-limiting viral upper respiratory infection
(especially in young children) to the more classic
symptoms of infectious mononucleosis marked by
fever, lymphadenopathy, pharyngitis, splenomegaly,
and generalized malaise [59]. The virus first enters
via the oropharynx, where it infects mucosal epithelial
cells and then invades resting B cells. The result is the
recruitment of EBV-specific T cell subsets that control
the ongoing lytic process. The majority of adults (ap-
proximately 90%) are infected with EBV. EBV persists
by a combination of latency and/or productive replica-
tion in B cells and in oral epithelial cells, respectively.
Control of EBV therefore relies on a potent EBV-
specific memory T cell response with approximately
4% of the T cell compartment dedicated to maintain-
ing the EBV-infected B cells at approximately 1% [60].
However, disruption to this balance and immune-
mediated control results in the potential for B cell lym-
phoproliferation as observed postallogeneic HCT.
Viral Latency and EBV Infections/
Lymphoproliferations
EBV-associated malignancies express certain anti-
genic patterns that represent latent viral-specific gene
expression. This heterogeneous group of lymphomas
can be subdivided based on their prevalence among
immunocompromised versus immune-competent pa-
tient populations [61]. The immunogenicity increases
with types I (eg, Burkitt’s lymphoma) being the least
immunogenic and type III being the most immuno-
genic. A fourth latency-type pattern exists in healthy
EBV-seropositive adults and is represented by
expressed gene products within resting CD231 B cells.
Type III latency express all nine known latency-
associated gene transcripts, RNAs, and proteins:
EBNA1, EBNA2, LMP1, LMP2, BARTs, EBNA la-
tent protein (EBNA-LP), and the immunodominant
EBNA proteins 3A, 3B, and 3C. Type III latency tu-
mors generally arise in the immune-suppressed host,
particularly recipients of allogeneic HCTs and pa-
tients with primary immunodeficiencies including
WAS, SCID, and X-linked lymphoproliferative dis-
ease (characterized by mutations in a gene, SH2DIA,
dramatically affecting CD81 T cell function) [62].Chronic Active EBV (CAEBV)
In rare instances, patients develop a chronic, symp-
tomatic infection with EBV. CAEBV is described as
a severe, chronic illness lasting greater than 6 months
in duration beginning as a primary infection, histo-
pathologic evidence of organ disease, and evidence of
EBV viral proteins or nucleic acids in the affected tis-
sues [63,64]. These patients typically exhibit chronic
symptoms including lymphadenopathy secondary
to lymphoproliferation, intermittent fevers, and
hepatosplenomegaly [63,65]. Although primary EBV
infection typically involves resting B cells, CAEBV
encompasses EBV-related lymphoproliferative dis-
eases involving B cells, T cells, and NK cells. Patients
may also present with a hemophagocytic syndrome
secondary to chronic, active viral infection [64,66].
The predominant cell type involved with CAEBV dis-
ease suggests a pattern of genetic vulnerability with
a predilection of T cell and NK cell varieties affecting
those of Asian, and Central/South American ethnic-
ities and B cell varieties involving patients fromWest-
ern countries. The only proven curative treatment for
this spectrum of disorders is allogeneic HCT, but
these patients can have significant problems with
EBV reactivations early after transplant, especially if
the donor is EBV seronegative [67].
PTLD
PTLD is characterized by four major histologic
subtypes (early lesions, monomorphic, polymorphic,
classic Hodgkin lymphoma-type) [68], all associated
with EBV infection. It arises because of the severe
T cell dysfunction caused by the immunosuppressive
medications used to prevent graft rejection or
GVHD. Symptoms and signs can include fever,
lymphadenopathy, fulminate sepsis, or mass lesions
in lymph nodes, spleen, or central nervous system. Af-
ter HCT, the disease is predominantly derived from
donor B cells and occurs within the first 3 to 6 months
of the posttransplantation period. Risk factors include
utilizing a T cell-depleted stem cell product for
transplant, the degree of HLA-mismatch between do-
nor and recipient, the degree and duration of
immunosuppression, and the usage of antithymocyte
globulin after reduced-intensity transplantation
conditioning [69-72].Treatment with Pharmacologic Agents and
Monoclonal Antibodies
After allogeneic HCT, standard of care is to mon-
itor EBV PCR levels. If tracked over time, this sensi-
tive, but nonspecific laboratory value can indicate
viral reactivation and therefore eminent or active
PTLD [69-73]. However, many variables exist with
these assays including the differences between the
thresholds observed from different laboratories as
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mononuclear cell-based assays [73].
A variety of therapeutic approaches to lymphopro-
liferative disorders (LPD) post-HCT have been
explored. Although withdrawal of immunosuppression
may be effective, it may not always be feasible espe-
cially in the setting of GVHD.Moreover, the develop-
ing donor-derived immune system may not provide
sufficient immune recovery to eradicate the EBV-
infected B cells. Chemotherapy regimens such as
R-CHOP and EPOCH-R have been successfully
used to treat LPD after solid-organ transplantation.
However, after HCT, mortality is high secondary to
significant toxicity [74]. Other drugs including inter-
feron-a2b, intravenous immunoglobulin, and antiviral
agents such as acyclovir have also been used to treat
LPD in this setting. However, a limitation with the
use of antiviral agents is that EBV-transformed cells
are latently infected, and these drugs only block active
herpes virus replication and do not affect the growth of
cells that are already transformed. The use of mono-
clonal anti-B cell antibodies such as anti-CD20 has
become standard for the treatment of this disease
with overall response rates ranging from 55% to
100% [75-77]. However, there are potential hazards
of CD20 therapy, as the profound B cell depletion
may further exacerbate immunodeficiency in
transplant recipients and may result in the selection
of a CD20-negative population of proliferating B
cells. Despite these ongoing treatments, PTLD
oftentimes recurs because cellular immunity against
EBV has not been restored [78]. Hence, efforts have
been focused on novel strategies to restore EBV-
specific T cell immunity after allogeneic HCT.
T Cell Therapies
Donor lymphocyte infusions or unmanipulated
allogeneic T cells
Many donors are seropositive for EBV and there-
fore possess a robust repertoire of cytotoxic T cells
against the highly immunogenic type III latency anti-
genic pattern produced by the virus. Infusion of these
donor cells serves as a therapeutic option against
PTLD in the post-HCT setting. The EBV-specific T
cell precursors in unmanipulated donor lymphocyte in-
fusions prove to be highly effective in controlling lym-
phoproliferation with response rates as high as 70%
and as early as 2 to 4 weeks postinfusion. However,
this is also associated with a significant incidence of
GVHD [79,80]. Recent work has shown that by
transducing herpes-associated thymidine kinase sui-
cide genes into donor T-lymphocytes, physicians can
treat PTLD and administer acyclovir to eradicate any
infused effector cell population that causes GVHD
[81,82]. However, concerns with this approach
include the development of an immune responseagainst unwanted herpes viral antigens and the usage
of antiviral medication that may interfere with
posttransplant care. To circumvent these issues, our
group has designed a novel suicide gene expressing an
inducible caspase-9 that, when bound to a synthetic
dimerizer, causes apoptosis in.90% of cells [83,84].
Donor-derived EBV-specific CTLs
Donor-derived, EBV-transformed LCL cell lines
prepared in the laboratory express the same type III la-
tency pattern as PTLD [73,85]. Thus, LCL act as
efficient antigen-presenting cells and can be used to
generate donor-derived EBV-specific CTLs. The
resultant T cell product usually contains both CD4
and CD81 T cells that recognize multiple latent and
lytic viral antigens and when infused into patients, or-
chestrate an effective and safe immune response against
PTLD without unwanted side effects such as GVHD
[78,86,87]. Our institution completed a 12-year review
of 114 patients who received EBV-specific CTLs for
PTLD.One hundred one of these patients received in-
fusions as prophylaxis and the remaining 13 as treat-
ment for active disease. Of the patients receiving
prophylactic infusions, none developed PTLD. Eleven
of 13 patients with active disease at the time of infusion
remained in complete remission that was sustained
with no recurrence. None of the patients receiving
CTLs developed de novo GVHD after infusions, and
only four patients experienced localized, but reversible
swelling at sites of disease during therapeutic response
[88]. Finally, financial analysis showed CTL therapy
wasnotonly efficaciousbut could also allot a substantial
savings when compared with the expenses associated
with repeated administrations of Rituximab [89].
Other groups have examined protocols that acquire
EBV-specific CTLs more rapidly. Three patients with
late-stage and three patientswith early-stagePTLDre-
ceived EBV-specific T cells isolated from donor blood
cells stimulated for only 36 hourswith a pool of 23EBV
peptide epitopes from 11 EBV antigens. This was fol-
lowed by isolation of responding, antigen-stimulated
T cells by antibody-mediated surface interferon-
gamma capture and immunomagnetic separation. Al-
though the three patients with late-stage disease failed
to respond, the remaining three had complete and
stable remission with two-thirds remaining free of
EBV-associated disease for more than 2 years [90].
An additional report showed the successful infusion
of rapidly acquired (less than 1 day) EBV-specific
CTLs into a patient from a haplotype parent donor.
This was achieved using magnetically labeled peptide
tetramers in order to select for T cells specific to an
EBV epitope [91]. In both studies, multiple organ
involvement and high EBV titers resolved with
continued remission; however, other modalities were
implemented concurrently including reduction of
immunosuppression and treatment with Rituximab.
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An additional strategy to bypass the lengthy time it
takes to manufacture patient-specific EBV-specific
CTL products is to produce a bank of allogeneic
EBV-specific CTLs so that a closely HLA-matched
product can be administered to patients with PTLD
[92]. Based on the success of a phase I/II study where
three of eight patients with PTLDshowed complete re-
mission after infusion of ‘‘third-party’’ CTL, a larger
phase II study was conducted with 33 patients. Patients
were eligible if they haddevelopedPTLDafterHCTor
solid-organ transplantation and had failed conventional
therapy. Response rates of 64%and52%were observed
for 5 weeks and 6 months respectively, postinfusion.
Further analysis showed that response rates were im-
proved for patients after HCT and when the donor
source was as closely HLA matched to the recipient as
possible [93,94]. Another report showed the
effectiveness of infusing third-party EBV-specific
CTLs with complete remission of central nervous sys-
tem PTLD lesions in two of three patients [95]. In the
UCB transplantation setting, two patients with EBV-
associated diffuse large B cell lymphoma after UCB
transplantation received third-party partially HLA-
matched EBV-specific CTLs. Both had failed Rituxi-
mab and a decrease of immunosuppressive medication.
After receiving five to nine CTL infusions, both pa-
tients achieved complete remission of their disease
[96]. Our institution has also developed a bank of
multivirus-specific CTLs targeting EBV, CMV, and
adenoviral antigens. Of the 47 HCT patients who re-
ceived infusions matched for 1-3 of six HLA antigens,
five had refractory PTLD. Two of these patients
achieved a sustained complete response [97]. In sum-
mary, these studies show that third-party ‘‘off-the-
shelf’’ virus-specific T cell products have therapeutic
potential and appear to have lessened the concern that
HLA disparity could potentially cause an unwanted al-
loreactive immune response in the recipient.
Conclusion
Tcell-based immunotherapies have proven to be an
essential part of our armament against EBV-associated
lymphoproliferative disease postallogeneic HCT.
EBV-specific CTLs have proven to be highly effective
in treating type III latency disease such as PTLD in
the HCT setting without the unwanted side effect of
alloreactivity such as GVHD. Ongoing research is
focused on strategies to rapidly treat patients with early
evidence of disease either using rapid CTL generation
approaches or third-party ‘‘off-the-shelf’’ products.ACKNOWLEDGMENT
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